Genitourinary Cancer | Norton Healthcare

Indication: Genitourinary Cancer

A Phase III, Randomized, Open Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Car

Bladder Cancer

Sub-indication: Unresectable Locally Advanced or Metastatic Urothelial Cancer.

Line of Therapy: 1st Line. (Patients who have received prior definitive chemoradiation, adjuvant or neoadjuvant for locally advanced disease are eligible provided that progression to locally advanced or metastatic disease has occurred >12 months from the last therapy or >

Drug Study

Principal Investigator: Chandler Park, M.D.
Norton Cancer Institute

Sponsor: AstraZeneca

Learn more at

Email for more information:

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.